BB Biotech Q1 Results Shine Amid Biotech Market's Interest Rate Concerns

• BB Biotech had a solid first-quarter performance, with a return of 11.3% in CHF and 7.6% in EUR, including a dividend payout of CHF 2.00 per share
• The portfolio's total return (NAV) was 11.2% in CHF, 6.3% in EUR, and 3.8% in USD, slightly ahead of BB Biotech’s benchmark
• Net profit for the first quarter of 2024 was CHF 260 mn, a significant improvement from a net loss of CHF 254 mn in the prior-year quarter
• Dr. Thomas von Planta was elected as the new Chairman of the Board of Directors at the Annual General Meeting
• Portfolio adjustments in the first quarter involved capitalizing on gains from larger holdings and engaging in capital increases for certain companies
• Biotech markets remained volatile, with large portfolio positions experiencing value fluctuations due to delays in major clinical trial readouts and positive developments in smaller positions.

The next important date, Publication of quarterly financial report (as of Q1), at BB Biotech is on 26.04.2024.

BB Biotech

-0,12 %

+4,34 %

-1,42 %

-10,46 %

-6,69 %

-42,28 %

-30,02 %

+81,60 %

+686,08 %

ISIN:CH0038389992WKN:A0NFN3

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max